SERENACE

This brand name is authorized in Australia, Japan, New Zealand, South Africa

Active ingredients

The drug SERENACE contains one active pharmaceutical ingredient (API):

1 Haloperidol UNII J6292F8L3D - HALOPERIDOL

Haloperidol is an antipsychotic belonging to the butyrophenones group. It is a potent central dopamine type 2 receptor antagonist, and at recommended doses, has low alpha-1 antiadrenergic activity and no antihistaminergic or anticholinergic activity. Read about Haloperidol

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SERENACE Tablet	Health Products Regulatory Authority (IE)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N05AD01	Haloperidol	N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AD Butyrophenone derivatives
Discover more medicines within N05AD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 12519X, 2761H, 2763K, 2767P, 2768Q, 2770T, 3456X
Country: JP	医薬品医療機器総合機構	Identifier(s): 1179020C1191, 1179020F1210, 1179020F2038, 1179020F3255, 1179020F5037, 1179404A1070
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 1216, 1217, 1218, 1219, 1220
Country: ZA	Health Products Regulatory Authority	Identifier(s): G/2.6.5/96, K/2.6.5/72